Gerald Pfeffer1, A Micheil Innes1, Timothy E Shutt2. 1. Alberta Children's Hospital Research Institute, Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 2. Alberta Children's Hospital Research Institute, Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: timothy.shutt@ucalgary.ca.
We appreciate the interest in our work and the opportunity to discuss the diagnosis of peripheral neuropathy in the new family we describe [1]. While a nerve biopsy would have added to the evidence available regarding these cases, the hereditary neuropathy diagnosis was established based on the clinical picture, neurophysiology and family history (provided in detail in Supplemental Table 2 [1]). Subsequently, exome sequencing identified the MYH14p.R941L mutation in all affected individuals. As the R941L mutation was previously associated with axonal neuropathy [2,3], it was not considered necessary to include a nerve biopsy for clinical purposes, especially as this procedure is invasive and frequently has unpleasant permanent side-effects [4].The neuropathy was classified as axonal based upon the following: (a) predominantly small-fibre sensory loss, (b) absence of significant conduction velocity defect, (c) predominance of motor findings on neurophysiology, and (d) consistency with previously described cases with this mutation [2,3]. Since the publication of our work, we have obtained access to additional clinical records. Nerve conduction studies (NCS) performed in IV-1 at age 15 demonstrated CMAP reduction in distal legs with preserved conduction velocity, and normal sensory responses, indicating motor axonal polyneuropathy.Regarding the hearing loss, we agree that evoked potentials may have aided to further characterise these patients. Nonetheless, audiometric evaluations in IV-1 and IV-2 confirmed that hearing loss preceded clinical weakness in these participants, and likely represents phenotypic variability of MYH14-related disorders. It should be noted that several loss of function mutations in MYH14 are associated with non-syndromic sensorineural hearing loss without any peripheral neuropathy or reported mitochondrial dysfunction [5]. Given that the NMIIC protein encoded by MYH14 has many cellular functions, it is possible that the mechanistic underpinnings of hearing loss are independent of the underlying cause of the peripheral neuropathy associated with the R941L mutation.
Authors: Stanley Iyadurai; W David Arnold; John T Kissel; Corey Ruhno; Vicki L Mcgovern; Pamela J Snyder; Thomas W Prior; Jennifer Roggenbuck; Arthur H Burghes; Stephen J Kolb Journal: Muscle Nerve Date: 2017-02-20 Impact factor: 3.217
Authors: Walaa Almutawa; Christopher Smith; Rasha Sabouny; Ryan B Smit; Tian Zhao; Rachel Wong; Laurie Lee-Glover; Justine Desrochers-Goyette; Hema Saranya Ilamathi; Oksana Suchowersky; Marc Germain; Paul E Mains; Jillian S Parboosingh; Gerald Pfeffer; A Micheil Innes; Timothy E Shutt Journal: EBioMedicine Date: 2019-06-21 Impact factor: 8.143
Authors: Francesca Donaudy; Rik Snoeckx; Markus Pfister; Hans-Peter Zenner; Nikolaus Blin; Mariateresa Di Stazio; Antonella Ferrara; Carmen Lanzara; Romina Ficarella; Frank Declau; Carsten M Pusch; Peter Nürnberg; Salvatore Melchionda; Leopoldo Zelante; Ester Ballana; Xavier Estivill; Guy Van Camp; Paolo Gasparini; Anna Savoia Journal: Am J Hum Genet Date: 2004-03-10 Impact factor: 11.025